SCAI SHOCK Stage Classification Expert Consensus Update
A Review and Incorporation of Validation Studies
Published 31 January 2022
Srihari S. Naidu, MD, FSCAI; David A. Baran, MD, FSCAI; Jacob C. Jentzer, MD; Steven M. Hollenberg, MD; Sean van Diepen, MD, MSc; Mir B. Basir, DO, FSCAI; Cindy L. Grines, MD, MSCAI; Deborah B. Diercks, MD, MSc, FACEP; Shelley Hall, MD; Navin K. Kapur, MD, FSCAI; William Kent, MD, MSc; Sunil V. Rao, MD, FSCAI; Marc D. Samsky, MD; Holger Thiele, MD, FESC; Alexander G. Truesdell, MD, FSCAI; Timothy D. Henry, MD, MSCAI
Naidu S, Baran D, Jentzer J et al. JSCAI Jan 2022;1(1)
Since its development and release in 2019, the Society for Cardiovascular Angiography and Interventions (SCAI) shock stage classification for adult patients has been widely cited and increasingly incorporated, owing to its simplicity across all clinical settings, easily understood and visualized framework, and notable endorsement by relevant societies and organizations that manage cardiogenic shock (CS).
Ensuing validation studies over the course of the subsequent 2 years documented both its ease and rapidity of use as well as its ability to meaningfully discriminate patient risk across the spectrum of CS, including various phenotypes, presentations, and health care settings. Nonetheless, several areas of potential refinement have been identified to make the classification scheme more applicable across all settings and clinical time points, given that data from validation studies have provided useful information not previously available that could serve to significantly refine the classification.
With this background, a clinical expert consensus writing group of all relevant stakeholders was reconvened to re-evaluate and refine the SCAI SHOCK stage classification based on the existing literature and clinician feedback from real-world experience.
ISHLT endorsed this document in January 2022.
Read at JSCAIRelated Guidlines
-
ISHLT Advisory Statement on the Implications of Pandemic Influenza for Thoracic Organ Transplantation
-
Generic Drug Immunosuppression in Thoracic Transplantation
-
Revision of the 1990 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Heart Rejection
-
Present Status of Research on Psychosocial Outcomes in Cardiothoracic Transplantation— Review and Recommendations for the Field
-
Chronic Lung Allograft Dysfunction: Definition, Diagnostic Criteria, and Approaches to Treatment